Advertisement
Advertisement
U.S. markets close in 2 hours 47 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Regencell Bioscience Holdings Limited (RGC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
31.00+1.74 (+5.96%)
As of 12:13PM EST. Market open.
Advertisement

Regencell Bioscience Holdings Limited

First Commercial Building
11th Floor 33-35 Leighton Road
Causeway Bay
Hong Kong
852 2155 0823
https://www.regencellbioscience.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees13

Key Executives

NameTitlePayExercisedYear Born
Mr. Yat-Gai AuFounder, Chairman & CEON/AN/A1973
Ms. Michelle ChanFinancial ControllerN/AN/AN/A
Mr. Wai Hong ChungCOO & Chief Strategy OfficerN/AN/A1977
Dr. Yi-Chung Chao Ph.D.Chief Medical Officer & DirectorN/AN/A1964
Mr. Tien Hsiang ChauExec. OfficerN/AN/A1970
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Corporate Governance

Regencell Bioscience Holdings Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement